Investors showed renewed interest in Medicenna Therapeutics Corp, driving its stock price up by over 6% in yesterday's trading session.
Medicenna Therapeutics Corp (MDNA.TO) saw its stock price rise significantly yesterday, closing at CA$0.43, which is a 6.10% increase. This jump comes as the company makes strides in its therapeutic programs, capturing the attention of investors.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$37.84M
52W high
$1.97
52W low
$0.34
1W change
-1.14%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 635.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+635.6% Upside
Current Price
C$0.43
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
58.4%
Annualized
90-Day Vol
69.7%
Annualized
Trend (90d)
-9.5%
Annualized drift
90d Mean
C$0.42
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.43 | C$0.35 – C$0.53 |
| 60 trading days | C$0.43 | C$0.32 – C$0.57 |
| 90 trading days | C$0.42 | C$0.30 – C$0.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The recent rise in Medicenna's stock price points to potential growth in the biotech sector, especially as the company progresses with its therapeutic initiatives.
Medicenna's stock price increased by 6.10% yesterday.
The market cap of Medicenna Therapeutics Corp now stands at about CA$37.84 million, reflecting investor optimism following recent funding announcements.
Bull case
The closing of a public offering that raised around CDN$4.44 million gives Medicenna the capital it needs to support its leading programs. This funding could lead to further advancements and boost investor confidence.
Bear case
Even with the positive movement, investors should stay cautious. The biotech sector can be unpredictable, and without immediate news, stock performance may fluctuate.
Advertisement
Recent Developments Fuel Investor Interest
Medicenna's recent announcement about closing a public offering, which raised approximately CDN$4.44 million, likely contributed to the stock's surge. This funding will help the company continue developing its therapeutic programs, particularly in interleukin-2 (IL-2) Superkine treatments.
Market Reaction and Future Outlook
The positive market reaction to Medicenna's funding news shows growing confidence among investors. As the company advances its clinical programs and strengthens its patent portfolio, there may be more opportunities for growth. Investors should keep an eye on upcoming announcements and developments related to MDNA.TO.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
